Ligand-based substituent-anchoring design of selective receptor-interacting protein kinase 1 necroptosis inhibitors for ulcerative colitis therapy.

Author: Jing ZHU ¹ ; Meng XIN ¹ ; Congcong XU ¹ ; Yuan HE ² ; Wannian ZHANG ¹ ; Zhibin WANG ¹ ; Chunlin ZHUANG ¹
Author Information

1. School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
2. Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
Publication Type:Journal Article
Keywords: Necroptosis; RIP1; RIP3; Selectivity; Ulcerative colitis
From: Acta Pharmaceutica Sinica B 2021;11(10):3193-3205
CountryChina
Language:English
Abstract: Receptor-interacting protein (RIP) kinase 1 is involved in immune-mediated inflammatory diseases including ulcerative colitis (UC) by regulating necroptosis and inflammation. Our group previously identified TAK-632 (